(R)-1-(3-Fluoro-4-methylphenyl)pyrrolidine-3-carbamic Acid Tert-Butyl Ester | 474774-46-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (R)-1-(3-Fluoro-4-methylphenyl)pyrrolidine-3-carbamic Acid Tert-Butyl Ester
• 英文别名: tert-butyl N-[(3R)-1-(3-fluoro-4-methylphenyl)pyrrolidin-3-yl]carbamate
• CAS: 474774-46-4
• 化学式: C₁₆H₂₃FN₂O₂
• 分子量: 294.369
• InChiKey: RPAIMSBLOCOJSP-GFCCVEGCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-1-(3-Fluoro-4-methylphenyl)pyrrolidine-3-carbamic Acid Tert-Butyl Ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 生成 1-(2-bromophenyl)-3-[(3R)-1-(3-fluoro-4-methylphenyl)pyrrolidin-3-yl]urea
  参考文献：
  名称：

  Discovery of SB-705498: A potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development

  摘要：

  Small molecule antagonists of the vanilloid receptor TRPV1 (also known as VR1) are disclosed. Pyrrolidinyl ureas such as 8 and 15 (SB-705498) emerged as lead compounds following optimisation of the previously described urea SB-452533. Pharmacological studies using electrophysiological and FLIPR-Ca2+-based assays showed that compounds such as 8 and 15 were potent antagonists versus the multiple chemical and physical modes of TRPV1 activation (namely capsaicin, acid and noxious heat). Furthermore, 15 possessed suitable developability properties to enable progression of this compound into in vivo studies and subsequently clinical development. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.03.030
• 作为产物：
  描述：

  4-溴-2-氟甲苯 、 (R)-3-叔丁氧羰基氨基吡咯烷 生成 (R)-1-(3-Fluoro-4-methylphenyl)pyrrolidine-3-carbamic Acid Tert-Butyl Ester
  参考文献：
  名称：

  Urea-compounds active as vanilloid receptor antagonists for the treatment of pain

  摘要：

  该文描述了化合物(I)的公式，或其药学上可接受的盐或溶剂化物，其中R1，R2，P，P'，n，p，q，r和s的定义详见说明书，以及制备这样化合物的过程，包含这样化合物的制药组合物，以及这样化合物和组合物在医学上的应用。

  公开号：

  US08063078B2

文献信息

• Urea compounds active as vanilloid receptor antagonist for the treatment of pain
  申请人：Glaxo Group Limited

  公开号：EP2036902A2

  公开（公告）日：2009-03-18

  Certain compounds of formula (I), or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein R1, R2, P, P', n, p, q, r and s are as defined in the specification, a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and composition in medicine.

  某些式(I)化合物、 或其药学上可接受的盐，或其溶液，其中 R1、R2、P、P'、n、p、q、r 和 s 如说明书中所定义；制备此类化合物的工艺；包含此类化合物的药物组合物；以及此类化合物和组合物在医药中的用途。
• HETEROCYCLIC UREAS, THEIR PREPARATION AND THEIR USE AS VANILLOID RECEPTOR ANTAGONISTS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP1392651A1

  公开（公告）日：2004-03-03
• US8063078B2
  申请人：——

  公开号：US8063078B2

  公开（公告）日：2011-11-22
• [EN] HETEROCYCLIC UREAS, THEIR PREPARATION AND THEIR USE AS VANILLOID RECEPTOR ANTAGONISTS<br/>[FR] UREES HETEROCYCLIQUES, LEUR PREPARATION ET LEUR UTILISATION COMME ANTAGONISTES DU RECEPTEUR VANILLOIDE
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO2002090326A1

  公开（公告）日：2002-11-14

  The invention relates to compounds of formula (I) having Vanilloid Receptor (VR1) antagonist activity, processes for their preparation, to compositions containing them and to their use in the treatment of various disorders.